U.S., July 30 -- ClinicalTrials.gov registry received information related to the study (NCT07734077) titled 'Revumenib in Patients With Myelofibrosis' on July 24.
Brief Summary: This is a Phase Ib/II 2 study investigating the safety and efficacy of revumenib in two cohorts of participants with myelofibrosis. COHORT-1 will investigate the safety of revumenib as monotherapy in participants with myelofibrosis previously treated with a JAK inhibitor. Following confirmation of safety in COHORT-1, the study will proceed with enrollment in COHORT-2, which will evaluate the efficacy and safety of revumenib in combination with a JAK inhibitor.
Study Start Date: Dec. 01, 2026
Study Type: INTERVENTIONAL
Condition:
Myelofibrosis
Post-polycythemia ...